January 20, 2022 10:12 AM EST
Manufacturing

Man­u­fac­tur­ing woes con­tin­ue for Au­robindo af­ter FDA's warn­ing let­ter

Josh Sullivan

An ac­tive phar­ma­ceu­ti­cal in­gre­di­ent site in In­dia has been hand­ed a warn­ing let­ter from the FDA, fol­low­ing an Au­gust 2021 in­spec­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

How blue­bird's buy­out of­fer went from $100M up­front to $29M

Roche launch­es new re­search cen­ter with Har­vard in Boston area

What the FDA, NIH hear­ings tell us about drug and health pol­i­cy un­der Trump

Bay­er eyes cap­i­tal raise as it grap­ples with Mon­san­to cas­es

At $300M Kardi­gan start­up, for­mer MyoKar­dia team un­veils its first drug, and it comes from Io­n­is

sponsored

The per­fect storm: Why every­thing is in place for 2025 to be the year of GxP AI

A service from the Financial Times